Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Wednesday, August 2, 2017

UCSF Neurologist Played Key Role in MS Research Turning to B-Cells, Essential Step to Ocrevus


                                                                  
  
Click here to receive MS news via e-mail


Dr. Stephen Hauser, chair of the neurology department at the University of California San Francisco, was instrumental in the early research and later clinical trials that ultimately led to Ocrevus (ocrelizumab), the first therapy approved by the U.S. Food and Drug Administration (FDA) for both relapsing MS (RMS) and primary progressive multiple sclerosis (PPMS) patients.
Indeed, his work is testament to how scientific inquiry and determination might turn observations made in the lab into medicines for those in need.

Ocrevus is an antibody that targets CD20-positive B-cells, a type of cells from the immune system that are believed to contribute to myelin degeneration and neuronal damage, the hallmarks of MS. As such, and because of the efficacy and overall safety demonstrated in those clinical studies, Ocrevus holds considerable promise as an MS treatment — and one that might help at least some people with progressive disease.

Read More



MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 
Join us, opt-in here: www.register.msviewsandnews.org 
..............................

No comments: